A PHASE 2/3, MULTICENTER, RANDOMIZED OPEN LABEL STUDY OF ZANZALINTINIB VS EVEROLIMUS IN PARTICIPANTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NEUROENDOCRINE TUMOURS

Registry ID

XL092-311

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

EXELIXIS INC

Start date

2025-12-12

Last update

2025-10-01

Conditions

• NEUROENDOCRINE TUMORS

Related clinical trials

• PHASE 1 FIRST-IN-HUMAN (FIH), DOSE ESCALATION AND DOSE EXPANSION STUDY OF RYZ401, A NOVEL RADIOPHARMACEUTICAL THERAPY LABELED WITH ACTINIUM-225 (225AC), IN SUBJECTS WITH NEUROENDOCRINE TUMORS (NETS) AND OTHER SELECTED SOLID TUMORS EXPRESSING SOMATOSTATIN RECEPTORS (SSTRS)
• LESION-TO-LESION COMPARISON OF 68GA-HADOTATATE, 18F-DOPA, AND 18F-FDG PET/CT IN THE EVALUATION OF METASTATIC NEUROENDOCRINE TUMORS
• A RANDOMIZED, MULTICENTER, OPEN-LABEL, ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREATIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANRETIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS
• EVALUATION OF THE IN VIVO BIODISTRIBUTION AND RADIATION DOSIMETRY OF 18F-AMBF3-TATE FOR USE AS A DIAGNOSTIC RADIOPHARMACEUTICAL
• A PHASE II STUDY OF [68]GA-HA-DOTATATE PET/CT IN THE EVALUATION OF LIVER METASTASIS IN ADULTS WITH NEUROENDOCRINE TUMORS
• EVALUATION OF THE SAFETY AND SENSITIVITY OF 68GA-DOTATOC PET/CT FOR IMAGING NET PATIENTS

View on source registry